Errata

In the article “PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study,” by Civan et al. (J Nucl Med. 2023;64:372–375), in the subsection PSMA RLT Absorbed Dose and Efficacy, the fourth sentence provides the mean residence time of the lesions [not the mean effective half-life of the lesions]. The authors regret the error.

In the article “Prediction of Resistance to ¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers,” by Sartor et al. (J Nucl Med. 2023;64:1721–1725), the spelling of the third author’s name is Minqi Huang [not Minqui Huang]. The authors regret the errors.

In the article “Long-Term Nephrotoxicity of ¹⁷⁷Lu-PSMA Radioligand Therapy,” by Steinhelfer et al. (J Nucl Med. 2024;65:79–84), an exponent in the Chronic Kidney Disease Epidemiology Collaboration equation should be −1.209 [not 1.209]. The correct equation is eGFR = 141 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−1.209 × 0.993^age. The authors regret the error.

In the article “Dosimetry of [¹⁷⁷Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis,” by Ells et al. (J Nucl Med. 2024;65:1264–1271), there were errors in Table 2. The skeletal and nodal lesion values in the studies of Herrmann/Krause and Resch were reported incorrectly. The values from the Herrmann/Krause studies are 5.4 ± 6 Gy/GBq [not 14.6 ± 29.8 Gy/GBq] and 9.7 ± 12 Gy/GBq [not 12.5 ± 15.9 Gy/GBq] for skeletal and nodal lesions, respectively. The values from the Resch study are 7.7 ± 4.5 Gy/GBq [not 5.8 ± 3.1 Gy/GBq] and 5.8 ± 3.1 Gy/GBq [not 7.7 ± 4.5 Gy/GBq] for skeletal and nodal lesions, respectively. The authors regret the errors.